This podcast features Dr. Christopher Venner and his colleagues from the hematology community, Dr. Sylvia McCulloch, Dr. Arleigh McCurdy, and Dr. Chai Phua discussing the approach to the management of early rrMM in the Canadian context.
 
This episode of Science for the Real World is part of <a href="https://canadianhematologytoday.com/" target="_blank" rel="ugc noopener noreferrer">Canadian Hematology Today</a>, an open-access scientific journal for the hematology community.

Practical considerations in the management of early rrMM in the Canadian context

Prise en charge des patients atteints de LLC doublement exposée et réfractaire.

Addressing the management of patients with double exposed and refractory CLL

Sponsored by Bristol Myers Squibb.

CAR T-cell Therapy in 2025: Evidence, Safety, and Patient Selection

In this episode of &quot;Science for the Real World: Canadian Hematology Today,&quot; Dr. Peter Anglin hosts a discussion with Dr. Joshua Richter and Dr. Darrell White on the management of early rrMM in 2024, focusing on the role of selinexor and treatment sequencing.

The role of selinexor in early rrMM and sequencing in 2024.

Science for the Real World is designed to illuminate hot topics in Canadian healthcare through a series of conversations with Canadian clinicians. Canadian Hematology Today presents robust clinical perspectives and practical insights on the treatment and management of hematologic diseases.

Share

Science For The Real World: Canadian Hematology Today

Practical considerations in the management of early rrMM in the Canadian context

More episodes

View all episodes

1. Prise en charge des patients atteints de LLC doublement exposée et réfractaire.

4. Addressing the management of patients with double exposed and refractory CLL

3. CAR T-cell Therapy in 2025: Evidence, Safety, and Patient Selection

1. The role of selinexor in early rrMM and sequencing in 2024.